Vijaya Diagnostic Centre Ltd (VIJAYA) — shareholding pattern, promoter holding, financials and share price
About Vijaya Diagnostic Centre Ltd (VIJAYA)
Vijaya Diagnostic Centre Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as VIJAYA and on the BSE under scrip code 543350. Its ISIN is INE043W01024.
Vijaya Diagnostics Centre limited is a leading diagnostic medicare services provider in Southern India and offers comprehensive services that include nuclear medicine, radiology, laboratory, health check-ups and medical services. The company provides its services across 13 cities through its 81 diagnostic centers and 11 reference laboratories. [1]
Vijaya Diagnostic Centre is a leading integrated B2C diagnostic chain in India offering pathology and radiology services across an expanding hub-and-spoke network; founded in 1981, it operates 162 centres across 27 cities with NABL/NABH accreditations and advanced imaging capabilities including PET-CT, 3T MRI and automated labs.
The company delivered a robust Q3 FY26: revenue of INR 2,052 million, EBITDA INR 861 million (41.9% margin) and PAT INR 432 million (21.0% margin), with volume-led growth (tests +14.7% YoY) and improvements in revenue per test and per footfall, indicating strong unit economics.
Listed peers in Healthcare Service Provider: Metropolis Healthcare Ltd, Thyrocare Technologies Ltd, Nephrocare Health Services Ltd, Krsnaa Diagnostics Ltd, Suraksha Diagnostic Ltd, One Global Service Provider Ltd.
Valuation & Returns
10 Jul 2026At ₹1,389.45 a share on 10 Jul 2026, Vijaya Diagnostic Centre Ltd (VIJAYA) was valued at a price-to-earnings ratio of 82.65x against an industry P/E of 61.73x and a price-to-book of 17.97x on a book value of ₹77.33 per share as of Mar 2025. Solomo computes return on equity of 21.74% and return on capital employed of 23.84% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 82.65x
- Industry P/E
- 61.73x
- P/B
- 17.97x
- EPS (TTM)
- ₹16.81
- Book value / share
- ₹77.33
- ROE
- 21.74%
- ROCE
- 23.84%
- ROA
- 13.58%
- Debt / equity
- 0.4x
- Dividend yield
- 0.14%
- EBITDA margin
- 43.94%
- 52-week range
- ₹847.9 – ₹1,425
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Vijaya Diagnostic Centre Ltd (VIJAYA) reported revenue of ₹814 crore, net profit of ₹173 crore and earnings per share of ₹16.81. That compares with revenue of ₹681 crore and net profit of ₹144 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹219 crore and net profit ₹48 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 462 | 459 | 548 | 681 | 814 |
| Net profit (₹ cr) | 111 | 85 | 120 | 144 | 173 |
| EPS (₹) | 10.76 | 8.29 | 11.61 | 13.94 | 16.81 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 13.80% | 11.63% | 24.45% |
| Profit growth | 17.13% | 7.69% | 20.19% |
| Stock price CAGR | - | 45% | 37% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.51% of Vijaya Diagnostic Centre Ltd (VIJAYA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 11.66% and domestic institutional investors (DII) hold 31.61%. Promoters have pledged 2% of their holding. Market capitalisation was ₹14,297 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.
Largest disclosed public shareholders in Jun 2026: KOTAK SMALL CAP FUND 6.59%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA MUL 5.64%, AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F 3.51%, HDFC MUTUAL FUND - HDFC NIFTY SMALLCAP 250 INDEX F 3.34%, ICICI PRUDENTIAL QUALITY FUND 2.95%, HSBC MUTUAL FUND - HSBC AGGRESSIVE HYBRID FUND 2.69%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.51% | 2% | 11.66% | 31.61% | 47.49% |
| Mar 2026 | 52.51% | 1.5% | 13.38% | 29.93% | 47.49% |
| Dec 2025 | 52.6% | 1.5% | 15.1% | 28.59% | 47.4% |
| Sep 2025 | 52.6% | - | 18.27% | 25.34% | 47.4% |
| Jun 2025 | 52.63% | - | 19.56% | 24.07% | 47.37% |
| Mar 2025 | 53.05% | - | 19.36% | 23.72% | 46.95% |
| Dec 2024 | 53.91% | - | 17.54% | 24.63% | 46.09% |
| Sep 2024 | 53.91% | - | 18.14% | 23.46% | 46.09% |